My PD Story

Nancy and her husband outside
Care Partners

Nancy Carstens

My husband spent his career building commercial and industrial projects around the country. Many years ago, he lost his sense of smell, which he attributed to being around chemicals on project sites. He also developed chronic constipation, which we thought was related to traveling and not maintaining a proper diet.

In 2018, while living in Atlanta, GA, for a project, he lost 20 pounds. We thought it was because he was cooking for himself and not eating second helpings. In 2019, we were in London, where you do a lot of walking. I noticed that he was shuffling his feet, but he said it was his shoes or the flooring. This continued when we returned home.

One day I noticed a slight tremor, but he said it was just the way he was reaching for something. He didn’t take my concerns seriously until 2020, when he was at work and was too stiff to put on his jacket and had to ask for help.

We saw a neurologist early in 2021, who referred us to a Movement Disorders Specialist. That specialist made the diagnosis of Parkinson’s disease, saying that he had probably had it for 10 years.

My husband’s movement symptoms have responded well to medication. However, he quickly began to exhibit non-movement symptoms ranging from anxiety and language issues to now symptoms of dementia.

As for myself, along with being his care partner — and more recently, his caregiver — I try to turn our mess into our message by serving as an Ambassador for the Parkinson’s Foundation, an Executive Board Member for our local chapter and a Research Advocate.

My husband’s father also had Parkinson’s disease, and we have two daughters, so we were interested in learning whether there might be a genetic factor involved. We enrolled him in PD GENEration, the Parkinson’s Foundation genetic study. The process was incredibly easy, and his results did not show a genetic link.

It felt great to participate, both for us and to help advance research. It was also meaningful to be able to tell our daughters that no genetic link was determined.

Explore ways to volunteer with the Parkinson’s Foundation and become a Parkinson’s Foundation Ambassador. Sign up now.

My PD Story

Donna Parkhurst headshot
People with PD

Donna Parkhurst

Parkinson’s disease (PD) entered my life long before my own diagnosis. Not too many years ago, I walked the caregiving journey alongside my mother as she lived with Parkinson’s and eventually passed away from its complications. Watching someone you love face the progression of this disease is heartbreaking, and it gave me a deep respect for both the strength of people living with Parkinson’s and the quiet resilience of caregivers.

Because of that experience, when I was diagnosed with Parkinson’s myself, it felt surreal. Suddenly I was no longer just the caregiver. I was the patient.

Like many people newly diagnosed, I had to face the uncertainty that comes with Parkinson’s. Some days I function very well, but there is always the question in the background: what will the future look like? Learning to live with that uncertainty has been one of the biggest challenges.

Another realization was that Parkinson’s is about far more than tremors or movement. Many symptoms are invisible — fatigue, anxiety, brain fog, sleep disruption, constipation and stress sensitivity. These symptoms can affect daily life in ways that others may not see or fully understand.

What has helped me most is focusing on the things I can control. Staying active, managing stress, prioritizing healthy habits, and leaning on supportive relationships have all played an important role in how I live with Parkinson’s today.

I’m incredibly grateful for a loving and supportive husband and family who walk alongside me on this journey.

One unexpected gift of this diagnosis has been the opportunity to connect with others in the Parkinson’s community. I began sharing my experiences online to bring awareness to both the visible and invisible aspects of Parkinson’s. What I discovered is that many people living with Parkinson’s — and their caregivers — simply want to feel seen, heard and understood.

Those conversations have become deeply meaningful to me. If sharing my story helps even one person feel less alone, better informed, or more hopeful, then something good is coming from this difficult diagnosis.

Participating in research has also become important to me. I enrolled in PD GENEration, the Parkinson’s Foundation genetic study. The process was extremely straightforward — easy, painless and honestly very impressive in how they carried out the entire experience.

Participating made me feel seen and valued, and I felt honored to contribute to research that may help others in the future. I was also relieved to learn that I do not carry a known genetic component to pass on to my children.

This was my first time participating in a Parkinson’s research study, but it won’t be my last. I’m very open to participating in future studies whenever possible. I also shared my genetic results with my family.

What keeps me hopeful is the resilience of the Parkinson’s community and the progress being made in research and treatment. Organizations like the Parkinson’s Foundation play an essential role by providing trusted education, resources, and advocacy that empower people living with Parkinson’s and their families.

If I could give advice to someone newly diagnosed, it would be this: take a deep breath. Parkinson’s looks different for everyone, and many people live well for decades. Stay active, build a strong care team, and stay connected to others who understand the journey.

Parkinson’s has changed parts of my life, but it has also deepened my sense of purpose. Today, I try to use my voice to raise awareness, encourage others living with Parkinson’s, and remind people that even in the face of uncertainty, there is still life to be lived, community to be found, and hope to hold onto.

Explore ways to get involved with Parkinson’s research today. Visit our Join A Study page and learn more about PD GENEration, the Parkinson’s Foundation genetics study that offers genetic testing and counseling at no cost to participants.

Science News

Orthostatic Hypotension in Parkinson’s Raises Long-Term Fall Risk

Parkinson's Foundation Science News blogs

Orthostatic hypotension (OH) — a significant drop in blood pressure that occurs when you stand up — is one of the most common non-movement symptoms of Parkinson’s disease (PD). It can cause dizziness, blurred vision, fatigue, and difficulty thinking, which can lead to falls. Generally, OH is also associated with cardiovascular problems (issues with the heart). Together, these risks highlight the importance of understanding how OH impacts health outcomes, especially in people with Parkinson’s.

A new nationwide study, published in Parkinsonism & Related Disorders, explores the longer-term consequences for people with Parkinson’s who experience OH. The study was led by Hikaru Kamo, MD, PhD, a 2025 Melvin Yahr Parkinson’s Disease Clinical Research Award recipient. Dr. Kamo and his research team, based at the University of Florida’s Norman Fixel Institute for Neurological Diseases, also included collaborators from the Parkinson’s Foundation.

Study Results

Using a nationwide insurance claims database, the research team analyzed records from 111,368 adults with Parkinson's disease, of whom 2,598 had a documented diagnosis of OH. After using statistical methods to account for differences between the two groups — such as age, other medical conditions and medications — the team found that people with Parkinson's and OH had a 35% higher chance of experiencing a fall over five years compared to those with Parkinson's alone. They also accumulated more total falls over time.

However, despite long-standing concerns that OH might put extra strain on the heart and blood vessels, the study found no significant link between OH and major cardiovascular events such as heart attack or stroke.

Among those with OH who were taking commonly prescribed medications for the condition, such as midodrine or fludrocortisone, fall risk was 34% higher compared to those not on these drugs, with no added cardiovascular benefit.

However, the study authors suggest that the most likely explanation is that people with more severe OH symptoms are more likely to be prescribed medication for the condition, and as a result are more likely to experience falls regardless of medication use. At this point, it should not be considered a cause-and-effect relationship until additional studies investigate further.

Overall, these findings were consistent across analyses, suggesting that OH in Parkinson's is more likely to lead to problems with falls compared to cardiovascular issues. Therefore, treatment for OH in Parkinson’s should place a strong emphasis on fall prevention.

Highlights

  • People with Parkinson's and OH had a 35% higher chance of experiencing a fall over five years compared to those with Parkinson's alone. They also accumulated more total falls over time.
  • Despite concerns that OH might strain the heart and blood vessels, the study found no significant link between OH and major cardiovascular events such as heart attack and stroke.
  • Among those with OH, people taking common OH medications (such as midodrine or fludrocortisone) had a 34% higher fall risk compared to those not on these drugs, without any added cardiovascular benefit.
  • In people with Parkinson’s and OH, fall risk is the main safety concern compared to cardiovascular events.

What does this mean?

This study supports that orthostatic hypotension in Parkinson’s is more of a fall-risk issue instead of a cardiovascular one. While that is reassuring news on the heart-health side, it underscores the importance of addressing fall prevention as a top priority for people living with Parkinson's and OH.

This research also indicates that more studies are needed on the impact of OH medications. Current research suggests that OH medications primarily treat the symptoms of OH, rather than treating the underlying cause of the condition. While these results of this study show that fall risk is higher in people with Parkinson’s taking OH medication compared to those without medication, the authors suggest that this may be a misleading association. To determine a cause-and-effect relationship, further studies on this topic are needed.

How do these findings impact people with Parkinson’s right now?

Overall, the message to the Parkinson’s community is that OH should be viewed primarily as a mobility and safety issue rather than a heart problem. This study adds important evidence about the real-world impact of OH in Parkinson’s and points to the need for better fall-prevention strategies and further study of treatment approaches.

PD care should prioritize fall prevention strategies, regardless of OH status. For people with PD and care partners, this means greater emphasis on lifestyle approaches such as fall-prevention programs, physical therapy, balance training, home safety modifications and knowing if medications can increase fall risk.

If you experience OH symptoms — such as weakness, difficulty thinking, headaches and blurred or dimmed vision — discuss them with your doctor.

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD and orthostatic hypotension through our resources below, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions.

Advancing Research

Meet the Researcher Working to Restore Sleep in Parkinson’s

🧠 What will you learn in this article?

This article highlights a researcher working to understand how Parkinson’s disease (PD) impacts sleep. It discusses: 

  • How PD changes neuron behavior in a specific sleep-regulating region.
  • How results of this study can inform future treatments for sleep issues in people with PD.
  • How support from the Parkinson’s Foundation makes research like this possible.
Pamela Marcott headshot

Beyond the most visible movement-related symptoms, people with Parkinson’s disease (PD) also experience non-movement symptoms. These symptoms can be debilitating and are sometimes more difficult for care partners to recognize.

One common non-movement PD symptom is difficulty sleeping, often in the form of waking up frequently throughout the night. Pamela Marcott, MD, PhD, a recipient of a Parkinson’s Foundation Postdoctoral Fellowship, is casting a spotlight on the sleep-associated circuits of the brain to understand how exactly PD impacts sleep patterns. By uncovering the mechanisms behind PD-related sleep problems, she hopes to help advance new therapies for such disturbances.

While much of the neuroscience of sleep is still a mystery, researchers do know that staying asleep through the night requires a highly calibrated balance of different signals in the brain. These sleep signals are relayed through brain cells called neurons and can vary in frequency and intensity, depending on their purpose. If these signals become altered and imbalanced, sleep fragmentation occurs with "frequent changes between different sleep and wake states, leading to less consolidated and restful sleep,” said Dr. Marcott.

Under the mentorship of Alexandra Nelson, MD, PhD, and Ying-Hui Fu, PhD, at the University of California, San Francisco, a Parkinson’s Foundation Center of Excellence, Dr. Marcott is investigating how PD changes the behavior of neurons in a specific sleep-regulating region of the brain called the pedunculopontine nucleus (PPN). PPN neurons act like telephone operators, relaying important signals across the brain. Using mice with and without PD-like symptoms, she will measure how the disease affects the ability of PPN neurons to transmit their important sleep signals.

 “Results of this study will improve our understanding of the circuit mechanisms that regulate sleep disturbances in PD, which will inform future therapeutic treatments,” said Dr. Marcott.

After learning more about how PD changes the sleep-related neurons’ signaling ability, Dr. Marcott will then monitor the brains of the mice as they sleep. She will keep a close eye on how the PPN neurons activate during sleep phase transitions, as she believes PD causes these neurons to be overactive and lead to fragmented sleep.

Observing in real time how PD alters sleep regulation in the brain will provide a strong foundation for understanding how to treat this symptom and give restful nights back to people with PD.

“I have been both personally and professionally affected by Parkinson's disease and have dedicated my career to improving the lives of patients living with Parkinson's and their families.” - Dr. Marcott

“This award is a powerful acknowledgment not just of the work I've done, but also of the work I hope to do in the future to improve care for patients with Parkinson's disease,” said Dr. Marcott. “As a physician scientist in this space, I am committed to making meaningful discoveries in the laboratory that will benefit my patients, and I am excited to have the opportunity to start this phase of my career with the support of the Parkinson's Foundation.”

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

Science News

Treating Sleep Apnea May Lower Parkinson’s Risk

🧠 What will you learn in this article?

This article highlights a new study that found that untreated obstructive sleep apnea (OSA) may increase the risk of developing Parkinson’s disease. It discusses:

  • How up to 40% of people with Parkinson’s experience sleep apnea.
  • People with untreated obstructed sleep apnea had nearly twice the risk of developing Parkinson's disease compared to those without OSA.
  • Early continuous positive airway pressure (CPAP) treatment in those with OSA significantly reduced the number of Parkinson's cases.
  • Benefits of early CPAP use for people with Parkinson’s.
Parkinson's Foundation Science News blogs

Sleep problems are a common non-movement symptom for people who live with Parkinson’s disease (PD). However, a new large-scale study reveals that untreated obstructive sleep apnea (OSA) may actually increase the risk of developing Parkinson’s disease in the first place, but treating it with continuous positive airway pressure (CPAP) may help reduce that risk.

Obstructive sleep apnea is a condition where breathing repeatedly stops and starts during sleep due to a blocked or narrowed airway. This prevents the body from getting enough oxygen, disrupting sleep quality and putting stress on various organs, including the brain. An estimated 30 million Americans have OSA, though many remain undiagnosed.

Study Results

The study, published in JAMA Neurology, and led by researchers at Oregon Health & Science University and the Portland VA Health Care System analyzed electronic health records from veterans who received care through the Department of Veterans Affairs between 1999 and 2022.

Of the more than 11 million veterans included in the analysis, about 1.5 million (13.7%) had OSA. After adjusting for factors like age, obesity and cardiovascular conditions, the researchers found a strong link between untreated sleep apnea and Parkinson’s disease. Veterans with OSA showed 1.61 additional cases of Parkinson’s per 1,000 people at six years from OSA diagnosis compared to those without the condition. Compared to those without the condition, veterans with OSA were nearly twice as likely to develop Parkinson’s. The link between OSA and Parkinson’s was even more pronounced in female veterans.

OSA can be effectively treated using CPAP machines. Importantly, the study found that early CPAP treatment reduced the risk of developing Parkinson’s. Veterans who began CPAP use within two years of their diagnoses were about 30% less likely to develop Parkinson’s compared to those who didn’t use CPAP.

In addition, for those who did eventually get diagnosed with Parkinson’s, the study showed that using CPAP early after an OSA diagnosis was associated with a reduction in the rates of falls, fractures and mortality.

Man sitting in bed cannot sleep

Highlights

  • The study analyzed health records of more than 11 million U.S. veterans over a 23-year period.
  • People with untreated obstructed sleep apnea had nearly twice the risk of developing Parkinson's disease compared to those without OSA.
  • The link between OSA and Parkinson's risk was even stronger in female veterans.
  • Early CPAP treatment in those with OSA significantly reduced the number of Parkinson's cases.
  • For those who developed Parkinson’s, early CPAP use was linked to reduced risk of falls, fractures, and mortality.

What Does This Mean?

This research suggests that obstructive sleep apnea may be a modifiable risk factor for Parkinson’s disease — meaning it can potentially be treated. It is important to note that the results of this study are correlations; the study did not prove that sleep apnea causes Parkinson’s, or that CPAP can prevent the development of Parkinson’s. However, the links between OSA, CPAP use, and Parkinson’s highlight the importance of diagnosing and managing sleep disorders early.

Additionally, these results support similar findings from the dementia field, in which a study found that CPAP treatment of OSA was associated with reduced odds of developing dementia.

OSA is extremely common and underdiagnosed. The Global Burden of Obstructive Sleep Apnea study found OSA to be a widespread concern “estimated to affect nearly 936 million adults aged between 30 and 69 worldwide.” Because of how widespread OSA is, linking it to Parkinson’s means there is a large opportunity to reduce risk and improve outcomes through better detection and treatment.

What Do These Findings Mean for People with Parkinson’s Right Now?

While this research does not change day-to-day treatment for people already living with Parkinson’s, it reinforces the importance of addressing sleep problems, which are already common in Parkinson’s.

Poor sleep can worsen movement and non-movement symptoms, affect quality of life and impact overall health. Research continues to link sleep apnea with negative health outcomes. If you experience symptoms of sleep apnea, such as loud snoring, gasping during sleep or excessive daytime fatigue, talk to your doctor. A sleep study can determine if you have OSA, and treatments like CPAP can help improve your sleep quality and potentially support your overall health.

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD and sleep through our resources below, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions.

Videos & Webinars

Navigating Advancing Needs: Planning Ahead with Parkinson’s

November 20, 2025

As Parkinson’s disease progresses, care needs can become more complex—impacting daily routines, independence, and long-term planning. This webinar will help veterans, and their care partners prepare for the changes that may come with advancing Parkinson’s. We’ll explore strategies for proactive care planning, VA services to support evolving needs, and resources to maintain quality of life through each stage of the disease. 

Presentation Slides

Additional Resources

Presenters

Reversa Joseph, MD, MS
Director of Movement Disorders Clinic
Chalmers P. Wylie VA

Amanda Ripke, LCSW
Movement Disorders Clinic
Chalmers P. Wylie VA

Science News

Breathing Danger: Study Links Air Pollution to Lewy Body Dementia Risk

🧠 What will you learn in this article?

This article highlights a new study that found that living in an area with higher air pollution was linked to hospitalization for Lewy body dementia (LBD). It discusses: 

  • How 75-80% of people with Parkinson's eventually develop LBD. 

  • Possible causes behind the findings 

  • What this study means for people with PD today. 

Parkinson's Foundation Science News blogs

For years, researchers have suspected that the air we breathe might affect our brain health. Now, a study examining 56.5 million Americans reveals a troubling connection between living in a place with higher air pollution and Lewy body dementia (LBD) — a finding with significant implications for the Parkinson's disease (PD) community, as 75-80% of people with Parkinson's eventually develop LBD. 

Lewy body dementia is an umbrella term for two related conditions: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Both involve the accumulation of abnormal protein deposits called Lewy bodies — which contain clumps of alpha-synuclein protein — throughout the brain. While people with Parkinson's initially experience movement symptoms like tremor and rigidity due to Lewy bodies primarily in neurons within movement-control brain regions, most will eventually develop cognitive symptoms as these protein deposits spread to areas controlling memory and thinking. 

The study, which was supported by the Parkinson’s Foundation and led by 2019 Stanley Fahn Jr. Faculty Award recipient Xiaobo Mao, analyzed health records of 56.5 million Americans who used Medicare from 2000 to 2014, across 34,824 zip codes. Researchers matched the zip codes to exposure to PM2.5, tiny particles in the air that come from sources like vehicle exhaust, industrial emissions and wildfire smoke. These particles are so small they can penetrate deep into the lungs and the bloodstream. While PM2.5 is recognized as a health concern and risk factor for dementia, this is the first study to find a link between PM2.5 and Lewy body dementia.  

Study Results 

The analysis showed that there was a strong link between long-term PM2.5 exposure and higher risk for someone’s first hospital admission for LBD, indicating that living in a place with more air pollution is associated with a greater risk for LBD. 

To understand how air pollution could be connected to LBD, the researchers conducted experiments with mice. They found that long-term PM2.5 exposure caused brain shrinkage and cognitive deficits in normal mice, lending support to their initial findings. Interestingly, this effect disappeared in genetically engineered mice lacking alpha-synuclein—the protein that forms the characteristic Lewy bodies. This suggests that alpha-synuclein plays a crucial role in how air pollution damages our brains. 

Perhaps most striking, the research team discovered that PM2.5 exposure in mice engineered to display Parkinson's-like symptoms led to the development of what they call “PM-PFF”—a particularly harmful version of alpha-synuclein that is highly resistant to breakdown and especially toxic to brain cells. The team showed that this corrupted protein closely resembles the abnormal alpha-synuclein found in actual LBD patients.  

woman wearing a mask to protect from air pollution

When the researchers exposed mice engineered to develop Parkinson's-like symptoms to air pollution samples from China, the U.S. and Europe for two months, they all consistently produced dangerous “PM-PFF” protein formations, suggesting air pollution is a global concern to brain health. 

The team also compared gene expression activity patterns between PM2.5-exposed normal mice and human LBD patients, finding prominent similarities. This pattern match strengthens the evidence that air pollution isn't just correlated with dementia—it may actually cause the biological changes seen in the disease. 

Highlights 

  • The study analyzed health records of 56.5 million Americans who used Medicare in a 14-year period, residing in 34,824 zip codes. 

  • Living in an area with higher air pollution (higher long-term levels of PM2.5 particles) was linked to hospitalization for Lewy body dementia (LBD). 

  • In normal mice, long-term PM2.5 exposure caused brain shrinkage and cognitive deficits. These issues depended on the presence of alpha-synuclein, a protein associated with PD and LBD.  

  • In mice engineered to develop Parkinson's-like symptoms, PM2.5 exposure created what they call “PM-PFF”—a particularly harmful version of alpha-synuclein that's highly resistant to breakdown and especially toxic to brain cells. 

  • Gene activity patterns in PM2.5-exposed normal mice were similar to those in human LBD patients. 

What Does This Mean? 

This research provides the first clear biological explanation for how air pollution might trigger or accelerate the development of Lewy body dementia. The identification of PM2.5 as a specific risk factor means we now have a measurable, modifiable environmental target for disease prevention. 

This study, and others like it, have found a clear association between environmental toxicants and neurodegenerative diseases – which is important as this knowledge could inform and impact environmental policies.  

This study highlights the importance of reducing exposure to air pollution when possible and continuing proactive steps that support brain health, like regular exercise, quality sleep and staying proactive with medical care. 

What do these findings mean to the people with PD right now? 

While this research doesn’t change day-to-day treatment for people with PD right now, it strengthens what many in the Parkinson’s community have long suspected — that environmental factors play a real role in disease development and progression. Knowing that air pollution may contribute to Lewy body disease gives us a new area to monitor and advocates another reason to push for cleaner air and stronger environmental standards. 

If you are concerned about exposure to air pollution, or PM2.5 particles, talk to your doctor.  

Learn More 

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD and the topics in this article through our below resources, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions. 

What is PM2.5

Small particles in the air with a diameter of 2.5 micrometers or less that come from sources like vehicle exhaust, industrial emissions, and wildfire smoke. 

My PD Story

Kauê M. Costa, PhD, professional headshot
Researchers

Kauê M. Costa, PhD

2025 Impact Award 

Investigating How Neurons Rebalance Their Roles in Early Parkinson’s 

In Parkinson’s disease (PD), cognitive symptoms often appear years before movement symptoms begin. However, these cognitive symptoms — difficulties performing tasks involving decision-making and learning — are linked to many different diseases and therefore difficult to use as an indicator for PD without additional clinical evidence. 

Kauê M. Costa, PhD, recipient of a Parkinson’s Foundation Impact Award, is diving into the complex neuroscience of PD to better understand what causes cognitive PD symptoms to occur before movement symptoms. This research could help lead to improved treatments for PD cognitive symptoms and support earlier PD diagnoses. 

“This research has the potential to shed light on intrinsic mechanisms of adaptation to cell loss that could be leveraged for developing new treatments for the disease, and to identify early biomarkers of Parkinsonian degeneration, which could be used for early diagnosis and intervention.” – Dr. Costa 

As PD progresses, dopamine-producing neurons in the substantia nigra region of the brain lose function and break down. The most fragile of these neurons, and usually the first ones to degenerate, are located in the lateral substantia nigra (lSN) and are important for sending movement signals to another brain region called the dorsolateral striatum (DSL). 

Dr. Costa hypothesizes that as these lSN neurons break down in early PD, the neighboring neurons in the medial substantia nigra (mSN) attempt to “pick up the slack”, taking over the lost movement signaling responsibilities. However, doing so means sacrificing efficiency in their other role, which involves cognitive signaling. This could explain why cognitive symptoms appear first, as the brain reorganizes neurons to preserve movement signaling at the expense of cognitive signaling. 

Kauê M. Costa working on a computer in the lab

From his lab at the University of Alabama at Birmingham, Dr. Costa will test his hypothesis by measuring the abilities of rats to perform learning-based and movement tasks before and after they are induced with simulated PD. Using state-of-the-art brain monitoring technology, Dr. Costa will also record dopamine released by both lSN and mSN neurons over time, observing how they change and adapt as the simulated disease progresses and if they follow his prediction of reorganized signaling roles. 

By understanding what is happening in the brain in early PD to cause cognitive symptoms before movement ones, doctors could improve the ability to diagnose the disease earlier, treat cognitive symptoms more efficiently, and potentially delay additional symptoms.  

“This Impact Award will allow me to apply my expertise to solving an important question in Parkinson's disease pathology, which I have been thinking about since I was a graduate student,” said Dr. Costa. “I am grateful to the Parkinson's Foundation for the opportunity to pursue my interests in the intersection of basic and translational neuroscience.”  

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.  

Podcasts

Episode 184: Finding Relief: Bladder Issues in Parkinson’s

Many people with Parkinson’s disease experience urinary or bladder issues at some point in their journey. These symptoms can take different forms and may affect people differently based on gender. Recognizing the signs is the first step toward understanding how to manage them and when to seek care. 

In this episode, Dr. Ankita Gupta, MD, MPH, FACOG, a urogynecologist at University of Louisville Hospital, talks about common bladder issues in Parkinson’s, such as urinary frequency, urgency, and nocturia. She explains how these symptoms can affect quality of life and even contribute to social isolation, and she highlights treatment options that can help manage them. 

Released: October 14, 2025

Raise Awareness

Parkinson's Medications 101

a hand holding medications

Medication plays a key role in managing Parkinson’s disease (PD), but it’s only one part of a broader care plan.  

The following article is based on a Parkinson’s Foundation  Expert Briefing  exploring how medications fit into integrated, holistic Parkinson’s care, hosted by Danny Bega, MD, MSCI, associate professor of neurology, medical director and director of the Parkinson's Disease & Movement Disorders Center neurology residency program at Northwestern University Feinberg School of Medicine, a Parkinson's Foundation Center of Excellence. Dr. Bega is also the director of the Huntington's and Wilson’s diseases programs at Northwestern. 

Understanding the Dopamine-Parkinson’s Connection 

Parkinson’s is a progressive disorder linked to declining levels of dopamine, a brain chemical that influences movement, memory and many other vital body processes. Other brain chemicals, including norepinephrine and serotonin, can also be impacted in Parkinson's disease and influence symptoms.  

As Parkinson’s advances, the number of brain cells making dopamine continues to decrease, and remaining cells struggle to store and release it. This leads to slowness of movement, tremor, rigidity and other motor symptoms. It can also cause various non-motor symptoms, such as constipation, loss of smell and thinking changes. 

Managing Parkinson’s 

Parkinson’s is a complex disease. There is no standard treatment. However, medications — along with exercise, comprehensive care, a nutritious diet and mindfulness practices — can manage Parkinson’s symptoms and help you live well.  

Establishing a regular exercise routine soon after diagnosis may help slow disease progression and can improve movement, strength, balance and mood. It can also help you sleep better. Staying social and engaged can reduce feelings of loneliness.  

Your care team is equally important. Look for healthcare professionals with expertise in Parkinson’s, including a neurologist, speech-language pathologist, physical and occupational therapist, social worker and other healthcare professionals, to help manage your PD symptoms. Be sure to attend regular checkups. 

The Role of Medication 

Most Parkinson’s medications work to improve symptoms by either increasing dopamine in the brain or acting like dopamine. Levodopa is the most effective drug for managing Parkinson’s symptoms. During the course of Parkinson’s, most people will take levodopa at some point.  

Anxiety and depression can also be common in Parkinson’s and can impact well-being even more than motor symptoms. Treating these symptoms using a combination of medication, such as an SSRI, SNRI or mirtazapine — a tricyclic antidepressant drug — along with therapy, stress management and staying active, can significantly decrease disability.  

People newly diagnosed with Parkinson’s often wonder when to begin prescription medication. Studies show there is no benefit in holding off. Most doctors agree you should start medication when symptoms begin to bother you.  

Because no two people experience PD in exactly the same way, treatments vary from person to person, as does the rate of progression. However, knowing the typical stages of Parkinson’s can help you anticipate changes: 

  • In the first five years following diagnosis, you may find symptoms don’t significantly impact your daily life. Your doctor might recommend a clinical trial. Participation in Parkinson’s research can potentially give you early access to new treatments, improve care and lay the foundation for a cure.  

  • Within one to 10 years, as symptoms begin to interfere with activities, most people with Parkinson’s can expect a long-lasting, steady response to medication.  

  • Between five and 20 years after diagnosis, it becomes increasingly harder for the brain to store dopamine. Your body’s response to levodopa can become shorter and less efficient. This can lead to motor fluctuations — "on" periods, when medication works well, and "off" periods, when medication wears off and symptoms return. It is important to work closely with your doctor to adjust your treatment and find what works best for you. 

  • After 10 or more years of living with Parkinson’s, a person can experience more significant issues. Some people can develop significant memory and thinking problems. Trouble with balance, falls and freezing, a temporary inability to move, can also become an issue. Your doctor can discuss medication adjustments or drug therapies or provide a referral to the right healthcare professional for your needs, which might include a neuropsychologist, psychiatrist, or a speech or occupational therapist. 

Types of Medications Used in Parkinson’s 

It can be common for people with Parkinson’s to take a variety of medications, at different doses and different times of day, to manage symptoms. This can include: 

Dopamine agonists: Early on, drugs that stimulate dopamine in the brain, such as pramipexole, ropinirole and rotigotine, can usually treat Parkinson’s movement symptoms. Dopamine agonists pose less risk for dyskinesia — involuntary erratic movements that usually begin after a few years of levodopa treatment.  

Side effects can include nausea, dizziness, sleepiness, confusion and impulse control disorders, such as uncontrolled shopping, gambling, eating and sexual urges. Studies show 28% of people with Parkinson’s stop taking dopamine agonists due to side effects, while 40% need to add another medication within two years. 

Levodopa: Levodopa, the most effective drug for Parkinson’s movement symptoms, replaces dopamine in the brain. It is usually given in combination with the drug carbidopa to reduce nausea, a common side effect. Taking levodopa with meals can also reduce nausea, but protein may interfere with the drug’s effectiveness. About 2% of people taking levodopa stop due to side effects, while 15% need to add another medication within two years.  

Dyskinesia, also linked to levodopa, can often be managed by a dose adjustment or through direct treatment, using a medication called amantadine. It works by blocking NMDA, a chemical that causes extra movement. Immediate-release amantadine is also sometimes used alone for Parkinson’s movement symptoms. There is an increased risk of confusion and hallucinations with amantadine use in people over 75. It can also be associated with leg swelling, skin changes and other side effects.  

Anticholinergics: The medications trihexyphenidyl and benztropine are sometimes used to improve tremor or dystonia — painful, sustained cramping . They work by blocking acetylcholine, a brain chemical tied to movement. However, their use should be avoided in people 70 and older due to the risk of confusion and hallucinations. Anticholinergics can also be associated with blurred vision, dry mouth, constipation and urinary retention. 

Medications your doctor might consider to improve the effects of levodopa include: 

MAO-B inhibitors: Monoamine oxidase-B inhibitors rasagiline, selegiline and safinamide make more dopamine available to the brain. These medications can be used alone or in combination with levodopa to extend effectiveness. MAO-B inhibitors are generally well tolerated, but 70% of people taking them alone for Parkinson’s will need to add another medication within two years. 

COMT inhibitors: Medications such as entacapone and opicapone increase available levodopa in the brain by blocking the catechol-O-methyl transferase enzyme.  

A2A receptor antagonist: Istradefylline, an adenosine A2A antagonist, blocks adenosine at A2A receptors in the brain to reduce levodopa “off “time. 

Inhaled levodopa is often used with levodopa, as needed, for sudden “off” time. Injectable apomorphine can also be used on demand, for “off” time relief. Both medications can increase the risk of dyskinesia. 

It is important to work with your doctor to find the right balance for you. Your doctor might increase or decrease your levodopa based on your symptoms. For example, tremor, stiffness or mobility issues might benefit from an increase in levodopa. However, hallucinations, confusion and low blood pressure might improve with a decrease in levodopa. 

There are also strategies and medications to manage drooling, runny nose, sleep issues, gut issues, thinking changes and other Parkinson’s challenges. 

What if levodopa doesn’t seem to be working? 

If you are taking levodopa but aren’t seeing benefits, talk to your doctor. Here are some questions to ask: 

  • Is the symptom troubling you one that doesn’t respond well to levodopa? Could it be related to another health issue?  
  • Would you benefit from a referral to a rehabilitation therapist or another health professional? 
  • Could something be interfering with how your body is absorbing medication? Some people experience less benefit when taking levodopa with a high-protein meal. 
  • Do you have a condition that mimics Parkinson’s? 

It is also important to discuss whether your dose needs to be adjusted. For example, the effects of Sinemet, a form of levodopa, only last a short time — after 90 minutes half of it is gone. Your doctor might adjust the timing and dose of levodopa, use a longer-acting formulation or recommend taking your medications 30 minutes before or 60 minutes after eating a meal. 

Advanced Therapies 

If it becomes difficult to control motor fluctuations by adjusting oral medications, there are other options to improve medication absorption and reduce “off” time:  

  • Duopa therapy delivers carbidopa-levodopa gel directly to your intestine through a surgically placed tube.  

  • Foscarbidopa and foslevodopa (Vyalev) therapy uses a pump to steadily deliver a form of levodopa under the skin through a small tube called a cannula. A needle is used to place the cannula. 

  • Continuous apomorphine therapy (Onapgo) uses a pump to deliver continuous apomorphine through a fine needle placed under the skin.  

These medications require lifestyle adjustments, training to use and a commitment to good skin care to reduce the risk of irritation and infections. 

Options Beyond Medication 

More advanced Parkinson’s symptoms can sometimes benefit from other treatment strategies, such as deep brain stimulation (DBS) — which involves surgically implanting an electrical pulse generator connected to electrodes placed in the brain to address Parkindeep-brainson’s movement symptoms and some non-movement symptoms.  

DBS might be considered for someone who:  

  • lives with classic Parkinson’s disease  

  • has symptoms that respond to levodopa  

  • experiences frequent motor fluctuations and tremor, despite consistent medication dosing 

  • has bothersome dyskinesia 

Following DBS, many people can reduce their medications and still experience a reduction of their PD symptoms. The reduction in dose of medication can lead to decreased dyskinesia. 

Focused ultrasound, a non-invasive therapy, does not require a surgical incision. During the procedure, high-frequency sound waves are aimed at a specific area of the brain connected to tremor to relieve Parkinson’s tremor. Unlike DBS therapy, which is adjustable and reversible, focused ultrasound changes are permanent. 

If you have questions about PD treatment options, contact our Helpline at 1-800-4PD-INFO (473-4636) or Helpline@Parkinson.org. 

Learn More 

Explore our resources about medications to treat symptoms of Parkinson’s:  

Back to Top